

INTISARI

NI PUTU DEWI AGUSTINI, 2014. ANALISIS KESESUAIAN BIAYA RIIL PASIEN KEMOTERAPI KANKER NASOFARING DENGAN PENETAPAN BIAYA INA-CBG's TERHADAP PELAKSANAAN JAMINAN KESEHATAN NASIONAL DI RSUP SANGLAH DENPASAR TAHUN 2014, UNIVERSITAS SETIA BUDI, SURAKARTA.

Indonesia case base group (INA-CBGs) digunakan sebagai sistem tarif paket jaminan kesehatan nasional (JKN). Biaya pembayaran paket seringkali terdapat selisih antara tarif paket INA-CBGs dan tarif biaya riil yang seringkali dianggap tidak mencukupi. Tujuan penelitian ini untuk mengetahui besarnya perbedaan antara biaya riil dengan tarif paket INA-CBGs pada pasien kemoterapi kanker nasofaring rawat inap, mengetahui faktor yang mempengaruhi biaya riil pada pasien kemoterapi kanker nasofaring, dan melihat siklus kemoterapi pada pasien kanker nasofaring.

Rancangan penelitian ini bersifat *deskriptif analitik*. Data diambil secara retrospektif dari berkas klaim pasien kanker nasofaring rawat dengan jumlah total episode 152 dari 59 pasien. Analisis yang digunakan adalah *one sample t-test* untuk mengetahui perbedaan antara biaya riil dengan tarif INA-CBGs serta analisis multivariat untuk mengetahui faktor yang mempengaruhi biaya riil.

Hasil penelitian menunjukkan besar perbedaan antara biaya riil dengan tarif INA-CBGs kode C-4-13-I kelas perawatan I Rp.63.398.719, kelas perawatan II Rp.11.164.041, dan kelas perawatan III Rp.265.353.088 Pada C-4-13-II kelas perawatan III Rp.36.291.628. Pada C-4-13-III kelas perawatan I Rp.34.434.030, kelas perawatan II Rp.13.562.874 dan kelas perawatan III Rp.84.122.496. Faktor yang mempengaruhi pada tingkat keparahan I yaitu LOS ($p=0,030$), prosedur ($p=0,001$), kelas perawatan ($p=0,000$) pada tingkat keparahan II yaitu LOS ($p=0,002$) dan pada tingkat keparahan III yaitu LOS($p=0,041$). Pola siklus yang tidak teratur memiliki nilai rerata biaya riil tanpa kemoterapi lebih tinggi daripada pola siklus yang teratur.

Kata Kunci: INA-CBG's, Kanker nasofaring, Kemoterapi, Biaya Riil.

ABSTRACT

NI PUTU DEWI AGUSTINI. 2014. ANALYSIS ON THE COMPATIBILITY OF REAL COST AND INA-CBGs COST DETERMINATION IN NASOPHARYNGEAL CANCER CEMOTHERAPY PATIENT TO THE IMPLEMENTATION OF NATIONAL HEALTH INSURANCE IN SANGLAH CENTERAL GENERAL HOSPITAL OF DENPASAR IN 2014, THESIS, PHARMACY FACULTY. SETIA BUDI UNIVERSITY, SURAKARTA

Indonesian case base group (INA - CBGs) is used as a system of national health insurance package rates. Payment fee package often there is a difference package rates between INA - cbgs and real cost rates that are often considered to be insufficient. The purpose of this study to determine the magnitude of the difference between the real cost with fare package INA-CBGs in patients with nasopharyngeal cancer chemotherapy hospitalization. Determine the factors that affect the real cost of nasopharyngeal cancer chemotherapy patients, and see the cycles of chemotherapy in patients with nasopharyngeal cancer.

The design of this research is descriptive analytic. Data were obtained retrospectively from file claims nasopharyngeal cancer patients treated with the total number of episodes 152 of 59 patients. The analysis used is a one sample t-test to determine the difference between the real cost rate INA-CBGs and multivariate analysis to identify factors that affect the real cost .

The results showed a large difference between the real cost to the INA-CBGs tariff code C-4-13-I First class of treatment was IDR.63.398.719; second class of treatment was IDR.11.164.041, third class of treatment was IDR.265.353.088 In C-4-13-II third class of treatment was IDR.36.291.628 . In C-4-13-III the first class of treatment was IDR.34.434.030; second class of treatment was IDR.13.562.874 third clas of treatment was IDR.84.122.496. Factors affecting the severity I of the procedure (p = 0.030), LOS (p=0,030), and claa of treatment (p=0,000) in the severity II, LOS (p= 0.002) and in the severity III, LOS (p= 0.041), procedures (p=0,00) and a secondary diagnosis (p=0,00). The pattern of irregular cycles has a mean value of the real cost without chemotherapy is higher than a regular cyclic pattern.

Keywords: INA-CBG's, Nasopharyngeal Cancer, Chemoterapy, Real Cost